Navigation Links
Neuralstem Reports First Quarter Financial Results and Provides Business and Clinical Update
Date:5/10/2011

ROCKVILLE, Md., May 10, 2011 /PRNewswire/ --Neuralstem, Inc. (NYSEAmex: CUR)  reported its financial results for the three months period ended March 31, 2011 and provided a business and clinical update.  

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO)

"The Company reached several major milestones in the first Quarter of 2011.  Interim data from our Phase I trial for ALS was presented at the American Academy of Neurology Annual Meeting in April, where the principal investigator of the trial, Dr. Eva Feldman, reported the ground-breaking work was both feasible and safe," said Neuralstem's Chairman and Chief Scientific Officer Karl Johe, PhD. "We completed all of the transplantations for the first 12-patient cohort in our ALS trial in mid-April. Also, in February, the U.S. FDA Office of Orphan Products Development granted the Company orphan drug designation for the cell therapy treatment of ALS with its human spinal cord-derived neural stem cells (NSI-566RSC)."

"Further, after receiving approval from the FDA late in 2010 for our first small molecule drug  trial, NSI-189 for major depression, we began dosing in our phase 1a patients in February," said Dr. Johe. "Looking forward, we expect the FDA to approve the second part of the Phase I ALS trial this summer. The next group of patients will receive injections in the upper spinal cord area, where we believe that the injections can ultimately aid in the preservation of respiratory capacity for ALS patients. Additionally, we expect the NSI-189 major depression trial to proceed to Phase Ib with escalating dosing of depressed patients this summer.  The small molecule program has been strengthened by the addition of Maurizio Fava, MD, Director of the Massachusetts General Hospital Department of Psychiatry Clinical Trials Network and Institute, who is now consulting on the trial des
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstems Board
2. Neuralstem, Inc. Settles Litigation Against ReNeuron, Ltd.
3. Neuralstem, Inc. to Present At World Stem Cells and Regenerative Medicine Congress
4. Neuralstem Completes $5.25 Million Financing
5. Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update
6. Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.
8. Neuralstem to Present at the 11th Annual BIO CEO & Investor Conference
9. Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent
10. Neuralstem CEO to Speak on ALS Panel at World Stem Cell Summit
11. Neuralstem Reports Second Quarter Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Involution Studios , a healthcare software design ... Understanding Ebola . The goal of the ... follow informative tool for anyone wanting to know more ... , "As the news has spread in all directions ... not only a healthcare crisis with global impact, but ...
(Date:10/22/2014)... October 22, 2014 Physicians Choice ... cardiovascular pharmacogenetics menu, which enables healthcare providers to ... With PCLS’s evidence-based results, healthcare providers are better ... their therapy, while minimizing risks for adverse drug ... according to the FDA [1] more than 2.2 ...
(Date:10/22/2014)... -- Nuvilex, Inc. (OTCQB: NVLX) – According to the ... living with diabetes, with  that number expected to grow ... for diabetes treatments is approximately $500 billion.  ... pancreatic cancer.  Pancreatic cancer is the fourth most common ... the United States , and according to a ...
(Date:10/20/2014)... Oct. 20, 2014 Mapp Biopharmaceutical,s valiant ... antibody therapeutic to fight the Ebola outbreak will ... time-consuming the production of pharmaceuticals can be, according ... said that while some may be taken aback ... those with industry knowledge are well aware of ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... it has become the majority owner of First Choice ... the greater Harrisburg area. First Choice,s 13 clinics join ... providing high-quality rehabilitation in outpatient settings. ... as Select Physical Therapy will offer physical therapy and ...
... offering best-in-class clinical, commercial and consulting services to the ... a definitive agreement to acquire certain promotional and medical ... committed to divest in connection with obtaining regulatory approval ... transaction were not disclosed. The business will ...
... 17, 2012 Using growth factors derived from a ... Charles Runels have developed a simple, office-based procedure that ... sexual response. The preliminary results of this procedure, which ... a specific area on the upper wall of the ...
Cached Biology Technology:First Choice Rehabilitation Specialists Joins Select Medical 2inVentiv Health to Acquire SDI Promotional and Medical Audit Businesses From IMS Health 2inVentiv Health to Acquire SDI Promotional and Medical Audit Businesses From IMS Health 3inVentiv Health to Acquire SDI Promotional and Medical Audit Businesses From IMS Health 4inVentiv Health to Acquire SDI Promotional and Medical Audit Businesses From IMS Health 5"O-Shot™" May Improve Female Sexual Response 2"O-Shot™" May Improve Female Sexual Response 3
(Date:10/14/2014)... in Cancer Research shows SIRT6—a protein known ... promote the development of skin cancers by turning on ... sun-damaged skin cells. , Previously considered protective, SIRT6 is ... that help regulate genomic stability and prevent some of ... DNA damage, which can lead to cancer. This study, ...
(Date:10/14/2014)... – Scientists have sequenced the house fly genome for ... might expect from an insect that thrives in pathogen-rich ... Oct. 14 in the journal Genome Biology , ... and of how flies quickly adapt to resist insecticides, ... house flies (Musca domestica) carry and transmit more than ...
(Date:10/14/2014)... Sinai-led research team has discovered a new kind of stem ... cell that lines liver blood vessels, according to a study ... The existence of such a cell type contradicts current theory ... and may hold clues to origins of, and future treatment ... a single cell into a complex being made up of ...
Breaking Biology News(10 mins):Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2House fly genome reveals expanded immune system 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3
... -- When melatonin, a hormone secreted by the ... stem cells (MSCs) prior to their transplantation into the ... researchers in China found that the stem cells survived ... 80 percent of transplanted MSCs died within 72 hours ...
... of losers and a few lucky winners. This is the ... fish called Fouldenia , which first appears in the ... that wiped out more than 90 percent of the planet,s ... 359 million years ago created opportunities quickly exploited by a ...
... a body is like building a houseif you compromise structural ... a cellular level than in the case of epithelial sheets, ... the gut to mammary glands. As long as epithelial cells ... of building tissue barriers and constructing ducts goes smoothly. But ...
Cached Biology News:Melatonin pre-treatment is a factor that impacts stem cell survival after transplantation 2Melatonin pre-treatment is a factor that impacts stem cell survival after transplantation 3From obscurity to dominance: Tracking the rapid evolutionary rise of ray-finned fish 2From obscurity to dominance: Tracking the rapid evolutionary rise of ray-finned fish 3From obscurity to dominance: Tracking the rapid evolutionary rise of ray-finned fish 4A flip of the mitotic spindle has disastrous consequences for epithelial cells 2A flip of the mitotic spindle has disastrous consequences for epithelial cells 3A flip of the mitotic spindle has disastrous consequences for epithelial cells 4
... MDR1 Shift Assay provides a convenient method to ... transport of MDR1 substrates. Thus, the kit may ... small molecules act as transport substrates for MDR1. ... presence of MDR1 substrates, the MDR1 Shift Assay ...
... The wide and long ... of Polaroid gel documentation systems. ... holds the camera in place ... that allows photography on the ...
... tissue microarrays are derived from Paraffin embedded ... quality control procedures to ensure the highest ... assembled in one block, sectioned at a ... coated slides. Sections are large (3-5 mm ...
... from frozen embedded tissue blocks, which are ... ensure the highest quality. Tissues of each ... sectioned at a thickness of 7microns and ... (3-5mm in diameter) in comparison to core ...
Biology Products: